Biomarkers for pain assessment are needed for more accurate pain therapy treatment in patients unable to reliably self-report their circumstances such as patients with dementia, intubated patients, and infants. The authors of a study recently published in Biomarkers in Medicine, Soluble intercellular adhesion molecule-1: a potential biomarker for pain intensity in chronic pain patients, hypothesized that pain intensity might be assessable using inflammatory molecules measurable in serum.
3D Growth of Endothelial Cells During ISS Space Mission – The SPHEROIDS Project
The April 2017 issue of Biomaterials reports on an automated cell culture unit that was developed for the SpaceX CRS-ISS space mission that resulted in three dimensional growth of human endothelial cells in microgravity.
A spaceflight to the International Space Station, carried out in April – May 2016, included a study to examine endothelial cell (EC) behavior in respect to cellular proliferation and apoptosis under spaceflight conditions to examine the gravity dependency of EC tube formation.
Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.
Novel nonglycemic biomarker for metformin
The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial delivers more insight on biomarkers that have potential to help treat patients with dysglycemia.1 Hertzel C. Gerstein and colleagues report Growth Differentiation Factor 15 as a novel biomarker for the use and dosing of metformin, in a study published in Diabetes Care last month.
More commonly known as an inhibitory cytokine, high doses of IL-10 have been shown to lead to the activation and survival of antigen stimulated CD8 T cells. According to a study published in the Journal of Clinical Oncology, the investigators in this first-in-human, phase 1 clinical trial of IL-10 (AM0010), demonstrate antitumor activity and therapy tolerability in a pretreated population. The primary endpoint of the study was to establish safety, tolerability and the maximum tolerated dose. This goal appears to have been met, with a low incidence of adverse events, most of which were temporary or reversible. The dose-escalation study was followed by a renal cell cancer dose-expansion cohort.
By Sam LaBrie
Developing precision medicines for COPD is an important goal, as the disease is the third most common cause of death in the developed world and there are relatively few effective therapies. A recent study published in PLOS, Common Genetic Polymorphisms Influence Blood Biomarkers Measurements in COPD, explores the massive datasets from two cohorts, SPIROMICS and COPDGene, in a search for biomarkers linked to various aspects of COPD. Scientists combined single nucleotide polymorphisms (SNPs) and a custom MAP (Multi-Analyte Profile) of Myriad RBM’s serum biomarker assays to identify protein quantitative trait loci (pQTLs), i.e. genetic features that are correlated with variations in protein expression).
Data analysis revealed 527 SNPs that are associated with 38 protein biomarkers (pQTLs). For 13 of these proteins, the pQTL could explain >10% of the variation in expression levels seen in the 2 cohorts, with the strongest influence being ~75% of the change in expression of vitamin D binding protein. Several of the pQTLs show significant associations with disease phenotypes, including the pQTL linked to sRAGE, which has been previously associated with emphysema. A striking finding was that SNPs in the ABO blood group region of the genome are strongly associated with many protein biomarker levels. Interestingly, the ABO blood group and COPD have been linked in earlier studies, confirming that ABO status should be taken into consideration for future COPD studies.
The authors conclude that multi-omics studies like this one are important for understanding complex diseases like COPD.